Background: Because surgeons are the main gatekeepers to oncology services,
understanding how they make decisions related to referral for adjuvant therapies is …

Background Non-small cell lung cancer, breast cancer, and colorectal cancer are commonly
diagnosed cancers in Canada. Patients diagnosed with early-stage non-small cell lung …

Background: Adjuvant chemotherapy (act) for non-small-cell lung cancer (nsclc) is
associated with improved survival in the general population, but may be underutilized. We …

Introduction Adjuvant chemotherapy in non-small cell lung cancer (NSCLC) has become a
new standard of care. This study examines the uptake patterns for adjuvant chemotherapy …

AIMS: We sought (i) lung cancer clinicians' judgements about the smallest survival benefits
that would make the harms of adjuvant chemotherapy for non-small-cell lung cancer …

BACKGROUND Published studies have suggested that most patients with early stage breast
cancer are willing, for modest survival benefits, to receive 6 months of adjuvant …

Background: Clinical trials demonstrate improved survival for patients with completely
resected non-small-cell lung cancer (NSCLC) who receive adjuvant chemotherapy …

Objective Decision-making about adjuvant chemotherapy (ACT) for stage II colon cancer is
complex, particularly in light of clinical uncertainty regarding treatment benefits. Little is …

Introduction: In the fall of 2004, adjuvant chemotherapy for early stage non-small cell lung
cancer (NSCLC) patients was approved for coverage by the Alberta Cancer Board, the …

Background. The first step in shared decision making (SDM) is creating choice awareness.
This is particularly relevant in consultations concerning preference-sensitive treatment …